Real-World Evidence
IN A POST HOC, PSM ANALYSIS, BENLYSTA + ST WAS ASSOCIATED WITH REDUCED ORGAN DAMAGE PROGRESSION1
Based on the mean change in SDI from baseline to Year 5*
Primary endpoint

Results are descriptive.
Real-world studies cannot definitively establish causality and are designed to evaluate associations. Limitations are important to interpret results: post hoc, retrospective analysis; patients matched only on known variables; unmatched variables exist (eg, year of entry, patient populations, and data collection vs randomized controlled trials).
PSM = propensity score matching; SDI = SLICC/ACR Damage Index; ST = standard therapy; TLC = Toronto Lupus Cohort.
* Includes all patients with ≥5 years of follow-up.
IN A POST HOC, PSM ANALYSIS, BENLYSTA + ST WAS ASSOCIATED WITH SLOWED ANNUAL RATE OF ORGAN DAMAGE PROGRESSION1
Based on SDI score increases per year¶
Secondary endpoint
Annual rate of organ damage progression

Patients receiving BENLYSTA + ST were 61% less likely to progress to a higher SDI score over any given year of follow-up compared with patients on standard therapy alone.
Hazard ratio (95% CI): 0.39 (0.25, 0.61)
Results are descriptive.
Real-world studies cannot definitively establish causality and are designed to evaluate associations. Limitations are important to interpret results: post hoc, retrospective analysis; patients matched only on known variables; unmatched variables exist (eg, year of entry, patient populations, and data collection vs randomized controlled trials).
¶Includes all patients with ≥1 year of follow-up.